American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Professional Development

Services to support hematologists with continuing medical education and recertification

Policy Resources

Information on federal programs and policies affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
  • FDA Approves New Treatment for Rare Form of Hemophilia

    The U.S. Food and Drug Administration yesterday approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVII] deficiency).

  • FDA Approves New Drug to Treat a Form of Gaucher Disease

    The U.S. Food and Drug Administration today approved Cerdelga (eliglustat) for the long-term treatment of adult patients with the Type 1 form of Gaucher disease, a rare genetic disorder.

  • FDA Approves Idelalisib for Relapsed Chronic Lymphocytic Leukemia

    On July 23, 2014, the U.S. Food and Drug Administration (FDA) approved idelalisib (Zydelig® tablets, Gilead Sciences, Inc.) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.

  • FDA Approves an Oral Suspension of mercaptopurine

    On April 28, 2014, the U. S. Food and Drug Administration approved an oral suspension of mercaptopurine (Purixan ®, NOVA Laboratories Limited). Mercaptopurine is a 20 mg/ml oral suspension. Purixan is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen.

View all FDA alerts
View all policy news
back to top